Mary manages complex domestic and international intellectual property disputes, in both judicial and administrative forums, to protect Merck’s intellectual property rights and provide freedom to operate. This includes managing relationships with outside counsel, developing and coordinating global legal strategy, and providing legal advice and risk assessments to senior management in connection with actual or anticipated litigation. Current or recent matters include the areas of immuno-oncology (Keytruda), respiratory (Nasonex), endocrinology (Propecia), and vaccines (pneumococcal conjugate vaccines).
Mary has also managed a multi-jurisdictional trademark dispute concerning the use of the company name on the internet and in social media. In addition, Mary has experience with mediation, customs and judicial seizures, negotiating settlement agreements and providing advice on transfer agreements, manufacturing and supply agreements, authorized-generic agreements and out-licensing agreements involving patent assets. Mary has been recognized by Managing Intellectual Property Corporate IP Star and IAM Strategy 300: The World’s Leading IP Strategists
